|Application ||WB, IF, E|
|Other Accession||NP_055084, 73765552|
|Calculated MW||Predicted: 76 kDa; Observed: 80 kDa|
|Application Notes||ADAM29 antibody can be used for detection of ADAM29 by Western blot at 1 - 2 µg/ml. For immunofluorescence start at 20 µg/mL.|
|Target/Specificity||ADAM29; ADAM29 antibody is human specific. ADAM29 antibody is predicted to not cross-react with other ADAM family proteins.|
|Reconstitution & Storage||ADAM29 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year.|
|Precautions||ADAM29 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||May be involved in spermatogenesis and fertilization. Seems to be a non catalytic metalloprotease-like protein.|
|Cellular Location||Membrane; Single-pass type I membrane protein|
|Tissue Location||Expressed specifically in testes.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The ADAM (a disintegrin and metalloprotease) protein family plays a role in cell-cell and cell-matrix interface related processes, including fertilization, muscle fusion, secretion of TNFalpha (tumor necrosis factor alpha), and modulation of the neurogenic function of Notch and Delta (1-3). ADAM29 contains one disintegrin domain, one EGF-like domain and one peptidase M12B domain (2). It is highly expressed in testes (3) and may be involved in spermatogenesis and fertilization (4,5).
Wang F, Xu R, Zhu P, et al. Preliminarily functional analysis of a cloned novel human gene ADAM29. Sci. China C. Life Sci. 2001; 44392-9.
Xu R, Cai J, Xu T, et al. Molecular cloning and mapping of a novel ADAM gene (ADAM29) to human chromosome 4. Genomics 1999; 62:537-9.
Cerretti DP, DuBose RF, Black RA, et al. Isolation of two novel metalloproteinase-disintegrin (ADAM) cDNAs that show testis-specific gene expression. Biochem. Biophys. Res. Commun. 1999; 263:810-5.
Oppezzo P, Vasconcelos Y, Settegrana C, et al. The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia. Blood 2005; 106:650-7.
If you have any additional inquiries please email technical services at email@example.com.